



AB SCIENCE STOCK ELIGIBLE FOR SRD "LONG-ONLY" FROM FEBRUARY 24TH 2012

AB Science announces that its stock will be eligible for SRD "long-only"* on NYSE Euronext beginning Friday February 24th 2011. Starting on that date, any potential investor will be able to purchase AB Science stock through the Differed Settlement Service, benefiting from the leverage effect as well as a deferred payment.

Laurent Guy, CFO declares: "Admission to the SRD long only for shares of AB Science will give greater visibility and greater liquidity by allowing a new category of investors to get into position".

Upcoming publication: T1 consolidated results on April 16th (after market close)

About AB Science:

Founded in 2001, AB Science is a pharmaceutical company specialising in the research, development and commercialisation of novel targeted therapies for patients with cancer or other important diseases with unmet medical needs including inflammatory and central nervous system diseases.

AB Science has developed a proprietary portfolio of protein kinase inhibitors (PKIs), a new class of targeted molecules whose action is to modify signalling pathways within cells. AB Science's lead product, masitinib, has already been registered in veterinary medicine in Europe and the US, and is currently under development in 9 phase 3 human studies, including 8 on-going studies in pancreatic cancer, GIST, metastatic melanoma expressing JM mutation of c-Kit, multiple myeloma, mastocytosis, severe persistent asthma, rheumatoid arthritis, and progressive multiple sclerosis. The Company is headquartered in Paris, France, and is listed on Euronext Paris (Ticker: AB).

More information is available on our website: www.ab-science.com

Contacts Citigate Dewe Rogerson:

Agnès Villeret, Analyst and Investor Relations
agnes.villeret@citigate.fr
tel: + 33 1 53 32 78 95

Lucie Larguier, Analyst and Investor Relations
lucie.larguier@citigate.fr
tel: + 33 1 53 32 84 75

*The SRD 'Long Only' also means that investors can leverage purchases, but cannot sell securities short.